Align Technology Inc. (ALGN): One of the Best Stocks to Buy According to Bares Capital

Why It Matters

The earnings beat and renewed share accumulation signal renewed investor confidence in Align’s restructuring and global expansion, positioning the stock as a compelling growth play in the orthodontics market.

Key Takeaways

• Bares Capital holds ~609,000 ALGN shares, up 20% QoQ.
• Q1 2026 revenue $1.04 B, up 6.2% YoY.
• Non‑GAAP EPS $2.58 beats consensus $2.30 by 12%.
• Operating margin expanded to 21.5% after 2025 restructuring.
• Teen orthodontic shipments rose 4.8%, led by China, Latin America.

Pulse Analysis

Align Technology’s inclusion in Bares Capital’s small‑cap value roster underscores the firm’s appeal to institutional investors seeking steady cash‑flow businesses with upside potential. Bares Capital’s recent 20% quarterly increase to roughly 609,000 shares reflects confidence in the company’s strategic direction, especially after a period of share reductions that mirrored broader market volatility. The fund’s long‑term exposure since 2018, combined with its recent buying, highlights Align as a core holding rather than a speculative bet, reinforcing its credibility among value‑oriented portfolios.

The company’s Q1 2026 results illustrate how operational discipline can translate into top‑line growth. Revenue climbed to $1.04 billion, driven largely by expanding international demand, while non‑GAAP earnings per share surged to $2.58, outpacing consensus forecasts by more than 12%. The 21.5% operating margin marks a notable improvement, indicating that the 2025 restructuring—focused on cost efficiencies and supply‑chain optimization—has begun to generate tangible leverage. Moreover, Align’s teenage orthodontics segment, the largest untapped market, posted a 4.8% shipment increase, with China and Latin America emerging as key growth engines.

For investors, Align’s trajectory offers a blend of defensive stability and growth upside. The firm benefits from a durable demand base for clear‑aligner therapy, while its expanding footprint in emerging markets diversifies revenue streams beyond mature U.S. demand. Compared with high‑volatility AI stocks, Align presents a lower‑beta alternative with predictable cash generation, making it attractive for portfolios seeking exposure to health‑tech innovation without excessive risk. Continued international penetration and the maturation of the teen segment could further accelerate earnings, positioning Align Technology as a standout performer in the broader dental‑technology landscape.